Give your COPD Patients...

PERFOROMIST® Inhalation Solution for the maintenance treatment of COPD delivers the efficacy of formoterol fumarate in a nebulized form for your COPD patients.1

Quick Links for HCPs


PERFOROMIST® (formoterol fumarate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Important Limitations for Use:

  • PERFOROMIST is not indicated to treat acute deteriorations of COPD.
  • PERFOROMIST is not indicated to treat asthma. The safety and effectiveness of PERFOROMIST Inhalation Solution in asthma has not been established.
Perforomist (formoterol fumarate) product packaging

Twice-daily nebulized PERFOROMIST helps patients control their COPD symptoms1†:

In a 12-week clinical trial in moderate to severe COPD patients (N=351) evaluating the effect of PERFOROMIST (formoterol fumarate) on FEV1 improvement up to 12 hours.1,3

checkmark icon Maintained bronchodilation as indicated by sustained FEV1  AUC up to 12 weeks1,3†

  • Statistically significant FEV1 improvement vs. placebo at day 1 and week 121,3†
  • Tolerance to the effects of inhaled beta-agonists may occur with regularly scheduled, chronic use1

checkmark icon Provided rapid onset of bronchodilation that lasted up to 12 hours1,3†

  • Works in as few as 5 minutes1,3†
  • The median time to onset of bronchodilation was 11.7 minutes, defined as a 15% increase in FEV1,3†
  • 78% of patients achieved a 15% increase from baseline FEV1 following the first dose of PERFOROMIST Inhalation Solution1,3†
  • PERFOROMIST is not indicated to be used as a rescue medication1

checkmark icon Reduced rescue therapy use by up to 42% (-1.25 puffs/day)1,3†

checkmark icon Calm, deep, even breathing is sufficient1

checkmark icon Can be stored at room temperature for up to 3 months1

  • Longer than any other nebulized long-acting beta2-agonist

FEV1=forced expiratory volume in 1 second.

†A randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group study in 351 moderate-to-severe COPD patients evaluating the efficacy and safety of PERFOROMIST (20 mcg/2 mL twice daily) over 12 weeks. PERFOROMIST group (n=123); placebo group (n=114). Sustained improvement was measured by serial FEV1 for 12 hours postdose, the primary efficacy analysis compared with placebo when evaluated at endpoint. Also evaluated use of rescue albuterol during the trial.1,3